Sucampo Pharma (SCMP) Tops Q3 EPS by 2c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Sucampo Reports Third Quarter 2017 Financial Results
November 1, 2017 6:30 AM EDTCompany Increases 2017 Financial Guidance Based on Strong Performance Year to Date
Study Results for VTS-270 for Niemann-Pick Disease Type C1 Published in The Lancet
CPP-1X/sulindac Granted Fast-Track status by FDA for Adults with Familial Adenomatous Polyposis
FDA Accepted sNDA for AMITIZA for Pediatric Functional Constipation in Children 6-17 Years of Age, With Priority Review Designation
Company to Host Conference Call Today at 8:30 a.m. ET
... More